Emicizumab: latest news - GoINPHARMA
Sunday, 24 March 2019 - 22:44


FDA approves Roche’s Hemlibra, novel therapy for hemophilia A

Roche has announced that FDA has approved Hemlibra (emicizumab) for routine prophylaxis in adults and children with haemophilia A with factor VIII inhibitors.  Approximately 30% of haemophilia A patients can develop inhibitors against factor VIII replacement therapies. This puts them…

FDA, priority review for Genentech/Roche’s emicizumab in haemophilia A

Genentech, a member of the Roche Group, announced that FDA accepted a sBLA (Biologics License Application) and granted Priority Review for emicizumab as a prophylaxis treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. As part…